Business and politics collaborating in favour of open markets
Federal Councillor Guy Parmelin’s attendance at the Swiss Medtech members’ meeting – despite being engaged in global campaigns to reduce US tariffs and cement further free trade agreements – highlights the importance of the medtech industry. Following the pharmaceutical and watchmaking industries, this sector contributes the third largest share to Switzerland’s trade surplus. Guy Parmelin recognised the innovative strength of the sector and emphasised: «Switzerland’s success is directly linked to its integration in international supply chains and markets. We are working resolutely to strengthen favourable domestic framework conditions, while simultaneously promoting free trade and the reduction of hindering technical barriers.»
Authorisation for US medical devices – strategic opportunity for Switzerland
Access to medical products is a key issue in the ongoing talks being between Switzerland and the USA. Switzerland is dependent on innovative medical devices approved by the US Food and Drug Administration (FDA) – many of which currently reach the Swiss market too late, or not at all. In November 2021, the Swiss Parliament mandated the Federal Council to find a solution. Conversely, the USA also has a strategic interest in securing access to the Swiss market – it would be the first time that US medical devices are authorised for a European country. «The Federal Council must use the current window to move forward. It can adopt the necessary rules via ordinance, and strengthen security of supply and promote innovation in Switzerland,» says Damian Müller, President of Swiss Medtech.
Strengthen free trade – stabilise bilateral agreements
The export-orientated medtech industry requires access to reliable global markets – especially in these times of increasing uncertainty. For Damian Müller, it is clear that Switzerland must now step up its game: «Free trade agreements continue to gain in importance. To make our economy more resilient and diversified, it is crucial the agreement with India enters into force quickly, that negotiations with the Mercosur states are finalised, and that the existing agreement with China is updated». In addition, it is essential that the bilateral stabilisation package be successfully pushed across the finish line. The European Union (EU) is the most important sales market for the Swiss medtech sector. Approximately half of all medtech exports are destined for somewhere in Europe.
Swiss Medtech’s clear strategy – new campaign launched
The association strategy presented by Swiss Medtech Director Adrian Hunn hits the nail on the head. The association has defined clear priorities: Open markets, increased innovation, fair reimbursement, and moderate regulation. «International competition is incredibly tough. Switzerland must do everything possible to ensure favourable framework conditions for its medtech companies,» emphasised Adrian Hunn. Fittingly, the association chose the members’ meeting to launch the «Medtech means life» campaign – raising awareness of the industry’s significant contribution to innovation, healthcare, jobs, and overall economic wellbeing.
Swiss Medtech represents around 800 members in its role as industry association for Swiss medical technology. With 71,700 employees and a contribution of 11.9% to the positive trade balance, medical technology is an economically significant sector in Switzerland. Swiss Medtech advocates for conditions that enable the medtech industry to perform at peak capacity and provide first-class medical care.